EGFR expression is lower in thymic carcinomas compared to thymomas [35], and somatic mutations in EGFR are infrequent, which explains the limited efficacy of EGFR inhibitors in thymic epithelial tumors [36,37]. This evidence concerns the gene EGFR and thymic carcinoma.